Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $0.90
Previous CloseN/A
Volume29.92K
Average Volume (3M)270.56K
Market Cap
$73.67M
Enterprise Value$128.61M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$7.37M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 13, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding103,022,675
10 Day Avg. Volume271,950
30 Day Avg. Volume270,565
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)-52.23
Price to Sales (P/S)0.00
P/FCF Ratio-7.98
Enterprise Value/Market Cap1.75
Enterprise Value/Revenue26.77
Enterprise Value/Gross Profit98.30
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$2.75Price Target Upside310.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
VolitionRX News
PremiumCompany Announcements
VolitionRX Ltd. Earnings Call Reveals Promising Growth
PremiumCompany Announcements
VolitionRx Reports Strong Q1 2025 Performance
Bulls Say, Bears Say
Bulls Say
Licensing DealsA licensing deal could trigger a warrant exercise valued at roughly $7 million, and completion of the feline test would trigger a $5 million milestone payment.
Strategic PartnershipsThe company's strategy to drive widespread adoption of its patent-protected portfolio of Nu.Q assays via collaborations with major marketing partners in the human and animal health spaces is achievable and could drive the company to achieve highly favorable operating margins.
Bears Say
Market PerceptionThe market is discounting the likelihood in human health despite management statements related to ongoing discussions with potential partners and favorable clinical data in multiple indications.
RisksRisks include failure in clinical development, failure to secure license agreements, and going concern risk.
Ownership Overview
12.01% Insiders
1.29% Mutual Funds
18.04% Other Institutional Investors
67.83% Public Companies and
Individual Investors
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.40 and its highest was $0.90 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $73.67M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Aug 13, 2025 which is in 54 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on May 15, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.06.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.05.
How many shares outstanding does VolitionRX have?
VolitionRX has 103,022,675 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (310.45% Upside)
$2.75 (310.45% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $247.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.8%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.66%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-56.16%
Trailing 12-Months
Company Description
VolitionRX
VolitionRX (VNRX) is a life sciences company focused on developing blood-based diagnostic tests for various types of cancer and other significant diseases. The company operates primarily in the biotechnology sector and aims to provide non-invasive, accurate, and cost-effective diagnostic solutions through its proprietary Nucleosomics technology, which detects fragments of chromosomes, called nucleosomes, in the bloodstream.
VNRX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including significant revenue growth, reduced operating expenses, and progress in licensing and commercialization efforts across various segments. However, challenges such as a decline in cash position and uncertainties in revenue predictions were noted. Overall, the positive highlights outweigh the lowlights, indicating a promising outlook for the company.Read More>VNRX Stock 12 Month Forecast
Average Price Target
$2.75
▲(310.45%Upside)
Technical Analysis
Enzo Biochem
―
BioNano Genomics
―
Burning Rock Biotech
―
Biodesix
―
bioAffinity Technologies, Inc.
―